The preoperative pan-immune-inflammation value is a novel prognostic predictor for with stage I–III colorectal cancer patients undergoing surgery
Purpose The pan-immune-inflammation value (PIV) is useful for stratifying outcomes in patients with metastatic colorectal cancer. However, it is unclear whether preoperative PIV can predict the surgical outcomes of patients with stage I–III colorectal cancer who receive surgery. Methods The records...
Gespeichert in:
| Veröffentlicht in: | Surgery today (Tokyo, Japan) Japan), 2022-08, Vol.52 (8), p.1160-1169 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1169 |
|---|---|
| container_issue | 8 |
| container_start_page | 1160 |
| container_title | Surgery today (Tokyo, Japan) |
| container_volume | 52 |
| creator | Sato, Shun Shimizu, Takayuki Ishizuka, Mitsuru Suda, Kotaro Shibuya, Norisuke Hachiya, Hiroyuki Iso, Yukihiro Takagi, Kazutoshi Aoki, Taku Kubota, Keiichi |
| description | Purpose
The pan-immune-inflammation value (PIV) is useful for stratifying outcomes in patients with metastatic colorectal cancer. However, it is unclear whether preoperative PIV can predict the surgical outcomes of patients with stage I–III colorectal cancer who receive surgery.
Methods
The records of 758 patients with stage I–III colorectal cancer who received surgical treatment were retrospectively reviewed. The preoperative PIV was calculated as follows: (neutrophil count × platelet count × monocyte count)/lymphocyte count. The cut-off value was determined using a receiver operating characteristic curve for overall survival.
Results
The cut-off value of the preoperative PIV was 376. Five hundred sixty-eight patients (74.9%) had low values (≤ 376), and 190 (25.1%) had high values (> 376). Univariate and multivariate analyses revealed that the PIV (> 376/ ≤ 376) (HR 2.485; 95% CI 1.552–3.981,
P
60/ ≤ 60, years) (HR 1.988; 95% CI 1.038–3.807,
P
= 0.038), globulin-to-albumin ratio (> 0.83/ ≤ 0.83) (HR 2.013; 95% CI 1.231–3.290,
P
= 0.005) and postoperative complication (C–D grade III–V/0–II) (HR 1.991; 95% CI 1.154–3.438,
P
= 0.013). The Kaplan–Meier method and log-rank test showed significant differences in overall survival between patients with stage I–III disease with high (> 376) and low (≤ 376) PIVs.
Conclusion
The preoperative PIV is useful for predicting surgical outcomes in patients with stage I–III colorectal cancer. |
| doi_str_mv | 10.1007/s00595-021-02448-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2618914322</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2618914322</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-8e69871fe85f18476d6c9ac5c591f172c9374029a957b2e6a5e48e6be13beda03</originalsourceid><addsrcrecordid>eNp9UcFO3TAQtKpW5UH7Az1UPvZisJ04iY8VghIJiQs9W37OJhgl9qvtPMSNf-AP-yVdeLTHylpZ3p0Za3YI-SL4qeC8PcucK60YlwKrrjvWvCMbUVcNk52o3pMN17VgQmpxRI5zvueI6jj_SI4qxYXCsyHPt3dAdwniDpItfo8PG5hfljUA82Gc7bJgPwa6t_MK1GdqaYh7mJEVpxBz8e5FYPCuxERHrAdf7mgudgLa_3567vueujjHBK7YmTobHCT8pngIJdM1DJCm6MNE85omSI-fyIfRzhk-v90n5Oflxe35Fbu--dGff79mrmpFYR00umvFCJ0aRVe3zdA4bZ1ySotRtNLpqq251FardiuhsQpq5GxBVFsYLK9OyLeDLjr5tUIuZvHZwTzbAHHNRjai07hPKREqD1CXYs4JRrNLfrHp0QhuXsIwhzAMhmFewzANkr6-6a_bBYZ_lL_bR0B1AGQcBbRu7uOaAnr-n-wfBdyZBg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2618914322</pqid></control><display><type>article</type><title>The preoperative pan-immune-inflammation value is a novel prognostic predictor for with stage I–III colorectal cancer patients undergoing surgery</title><source>SpringerLink Journals - AutoHoldings</source><creator>Sato, Shun ; Shimizu, Takayuki ; Ishizuka, Mitsuru ; Suda, Kotaro ; Shibuya, Norisuke ; Hachiya, Hiroyuki ; Iso, Yukihiro ; Takagi, Kazutoshi ; Aoki, Taku ; Kubota, Keiichi</creator><creatorcontrib>Sato, Shun ; Shimizu, Takayuki ; Ishizuka, Mitsuru ; Suda, Kotaro ; Shibuya, Norisuke ; Hachiya, Hiroyuki ; Iso, Yukihiro ; Takagi, Kazutoshi ; Aoki, Taku ; Kubota, Keiichi</creatorcontrib><description>Purpose
The pan-immune-inflammation value (PIV) is useful for stratifying outcomes in patients with metastatic colorectal cancer. However, it is unclear whether preoperative PIV can predict the surgical outcomes of patients with stage I–III colorectal cancer who receive surgery.
Methods
The records of 758 patients with stage I–III colorectal cancer who received surgical treatment were retrospectively reviewed. The preoperative PIV was calculated as follows: (neutrophil count × platelet count × monocyte count)/lymphocyte count. The cut-off value was determined using a receiver operating characteristic curve for overall survival.
Results
The cut-off value of the preoperative PIV was 376. Five hundred sixty-eight patients (74.9%) had low values (≤ 376), and 190 (25.1%) had high values (> 376). Univariate and multivariate analyses revealed that the PIV (> 376/ ≤ 376) (HR 2.485; 95% CI 1.552–3.981,
P
< 0.001) was significantly associated with overall survival, as well as age (> 60/ ≤ 60, years) (HR 1.988; 95% CI 1.038–3.807,
P
= 0.038), globulin-to-albumin ratio (> 0.83/ ≤ 0.83) (HR 2.013; 95% CI 1.231–3.290,
P
= 0.005) and postoperative complication (C–D grade III–V/0–II) (HR 1.991; 95% CI 1.154–3.438,
P
= 0.013). The Kaplan–Meier method and log-rank test showed significant differences in overall survival between patients with stage I–III disease with high (> 376) and low (≤ 376) PIVs.
Conclusion
The preoperative PIV is useful for predicting surgical outcomes in patients with stage I–III colorectal cancer.</description><identifier>ISSN: 0941-1291</identifier><identifier>EISSN: 1436-2813</identifier><identifier>DOI: 10.1007/s00595-021-02448-6</identifier><identifier>PMID: 35015151</identifier><language>eng</language><publisher>Singapore: Springer Nature Singapore</publisher><subject>Medicine ; Medicine & Public Health ; Original Article ; Surgery ; Surgical Oncology</subject><ispartof>Surgery today (Tokyo, Japan), 2022-08, Vol.52 (8), p.1160-1169</ispartof><rights>The Author(s) under exclusive licence to Springer Nature Singapore Pte Ltd. 2022</rights><rights>2022. The Author(s) under exclusive licence to Springer Nature Singapore Pte Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-8e69871fe85f18476d6c9ac5c591f172c9374029a957b2e6a5e48e6be13beda03</citedby><cites>FETCH-LOGICAL-c371t-8e69871fe85f18476d6c9ac5c591f172c9374029a957b2e6a5e48e6be13beda03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00595-021-02448-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00595-021-02448-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35015151$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sato, Shun</creatorcontrib><creatorcontrib>Shimizu, Takayuki</creatorcontrib><creatorcontrib>Ishizuka, Mitsuru</creatorcontrib><creatorcontrib>Suda, Kotaro</creatorcontrib><creatorcontrib>Shibuya, Norisuke</creatorcontrib><creatorcontrib>Hachiya, Hiroyuki</creatorcontrib><creatorcontrib>Iso, Yukihiro</creatorcontrib><creatorcontrib>Takagi, Kazutoshi</creatorcontrib><creatorcontrib>Aoki, Taku</creatorcontrib><creatorcontrib>Kubota, Keiichi</creatorcontrib><title>The preoperative pan-immune-inflammation value is a novel prognostic predictor for with stage I–III colorectal cancer patients undergoing surgery</title><title>Surgery today (Tokyo, Japan)</title><addtitle>Surg Today</addtitle><addtitle>Surg Today</addtitle><description>Purpose
The pan-immune-inflammation value (PIV) is useful for stratifying outcomes in patients with metastatic colorectal cancer. However, it is unclear whether preoperative PIV can predict the surgical outcomes of patients with stage I–III colorectal cancer who receive surgery.
Methods
The records of 758 patients with stage I–III colorectal cancer who received surgical treatment were retrospectively reviewed. The preoperative PIV was calculated as follows: (neutrophil count × platelet count × monocyte count)/lymphocyte count. The cut-off value was determined using a receiver operating characteristic curve for overall survival.
Results
The cut-off value of the preoperative PIV was 376. Five hundred sixty-eight patients (74.9%) had low values (≤ 376), and 190 (25.1%) had high values (> 376). Univariate and multivariate analyses revealed that the PIV (> 376/ ≤ 376) (HR 2.485; 95% CI 1.552–3.981,
P
< 0.001) was significantly associated with overall survival, as well as age (> 60/ ≤ 60, years) (HR 1.988; 95% CI 1.038–3.807,
P
= 0.038), globulin-to-albumin ratio (> 0.83/ ≤ 0.83) (HR 2.013; 95% CI 1.231–3.290,
P
= 0.005) and postoperative complication (C–D grade III–V/0–II) (HR 1.991; 95% CI 1.154–3.438,
P
= 0.013). The Kaplan–Meier method and log-rank test showed significant differences in overall survival between patients with stage I–III disease with high (> 376) and low (≤ 376) PIVs.
Conclusion
The preoperative PIV is useful for predicting surgical outcomes in patients with stage I–III colorectal cancer.</description><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Original Article</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><issn>0941-1291</issn><issn>1436-2813</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9UcFO3TAQtKpW5UH7Az1UPvZisJ04iY8VghIJiQs9W37OJhgl9qvtPMSNf-AP-yVdeLTHylpZ3p0Za3YI-SL4qeC8PcucK60YlwKrrjvWvCMbUVcNk52o3pMN17VgQmpxRI5zvueI6jj_SI4qxYXCsyHPt3dAdwniDpItfo8PG5hfljUA82Gc7bJgPwa6t_MK1GdqaYh7mJEVpxBz8e5FYPCuxERHrAdf7mgudgLa_3567vueujjHBK7YmTobHCT8pngIJdM1DJCm6MNE85omSI-fyIfRzhk-v90n5Oflxe35Fbu--dGff79mrmpFYR00umvFCJ0aRVe3zdA4bZ1ySotRtNLpqq251FardiuhsQpq5GxBVFsYLK9OyLeDLjr5tUIuZvHZwTzbAHHNRjai07hPKREqD1CXYs4JRrNLfrHp0QhuXsIwhzAMhmFewzANkr6-6a_bBYZ_lL_bR0B1AGQcBbRu7uOaAnr-n-wfBdyZBg</recordid><startdate>20220801</startdate><enddate>20220801</enddate><creator>Sato, Shun</creator><creator>Shimizu, Takayuki</creator><creator>Ishizuka, Mitsuru</creator><creator>Suda, Kotaro</creator><creator>Shibuya, Norisuke</creator><creator>Hachiya, Hiroyuki</creator><creator>Iso, Yukihiro</creator><creator>Takagi, Kazutoshi</creator><creator>Aoki, Taku</creator><creator>Kubota, Keiichi</creator><general>Springer Nature Singapore</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20220801</creationdate><title>The preoperative pan-immune-inflammation value is a novel prognostic predictor for with stage I–III colorectal cancer patients undergoing surgery</title><author>Sato, Shun ; Shimizu, Takayuki ; Ishizuka, Mitsuru ; Suda, Kotaro ; Shibuya, Norisuke ; Hachiya, Hiroyuki ; Iso, Yukihiro ; Takagi, Kazutoshi ; Aoki, Taku ; Kubota, Keiichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-8e69871fe85f18476d6c9ac5c591f172c9374029a957b2e6a5e48e6be13beda03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Original Article</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sato, Shun</creatorcontrib><creatorcontrib>Shimizu, Takayuki</creatorcontrib><creatorcontrib>Ishizuka, Mitsuru</creatorcontrib><creatorcontrib>Suda, Kotaro</creatorcontrib><creatorcontrib>Shibuya, Norisuke</creatorcontrib><creatorcontrib>Hachiya, Hiroyuki</creatorcontrib><creatorcontrib>Iso, Yukihiro</creatorcontrib><creatorcontrib>Takagi, Kazutoshi</creatorcontrib><creatorcontrib>Aoki, Taku</creatorcontrib><creatorcontrib>Kubota, Keiichi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Surgery today (Tokyo, Japan)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sato, Shun</au><au>Shimizu, Takayuki</au><au>Ishizuka, Mitsuru</au><au>Suda, Kotaro</au><au>Shibuya, Norisuke</au><au>Hachiya, Hiroyuki</au><au>Iso, Yukihiro</au><au>Takagi, Kazutoshi</au><au>Aoki, Taku</au><au>Kubota, Keiichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The preoperative pan-immune-inflammation value is a novel prognostic predictor for with stage I–III colorectal cancer patients undergoing surgery</atitle><jtitle>Surgery today (Tokyo, Japan)</jtitle><stitle>Surg Today</stitle><addtitle>Surg Today</addtitle><date>2022-08-01</date><risdate>2022</risdate><volume>52</volume><issue>8</issue><spage>1160</spage><epage>1169</epage><pages>1160-1169</pages><issn>0941-1291</issn><eissn>1436-2813</eissn><abstract>Purpose
The pan-immune-inflammation value (PIV) is useful for stratifying outcomes in patients with metastatic colorectal cancer. However, it is unclear whether preoperative PIV can predict the surgical outcomes of patients with stage I–III colorectal cancer who receive surgery.
Methods
The records of 758 patients with stage I–III colorectal cancer who received surgical treatment were retrospectively reviewed. The preoperative PIV was calculated as follows: (neutrophil count × platelet count × monocyte count)/lymphocyte count. The cut-off value was determined using a receiver operating characteristic curve for overall survival.
Results
The cut-off value of the preoperative PIV was 376. Five hundred sixty-eight patients (74.9%) had low values (≤ 376), and 190 (25.1%) had high values (> 376). Univariate and multivariate analyses revealed that the PIV (> 376/ ≤ 376) (HR 2.485; 95% CI 1.552–3.981,
P
< 0.001) was significantly associated with overall survival, as well as age (> 60/ ≤ 60, years) (HR 1.988; 95% CI 1.038–3.807,
P
= 0.038), globulin-to-albumin ratio (> 0.83/ ≤ 0.83) (HR 2.013; 95% CI 1.231–3.290,
P
= 0.005) and postoperative complication (C–D grade III–V/0–II) (HR 1.991; 95% CI 1.154–3.438,
P
= 0.013). The Kaplan–Meier method and log-rank test showed significant differences in overall survival between patients with stage I–III disease with high (> 376) and low (≤ 376) PIVs.
Conclusion
The preoperative PIV is useful for predicting surgical outcomes in patients with stage I–III colorectal cancer.</abstract><cop>Singapore</cop><pub>Springer Nature Singapore</pub><pmid>35015151</pmid><doi>10.1007/s00595-021-02448-6</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0941-1291 |
| ispartof | Surgery today (Tokyo, Japan), 2022-08, Vol.52 (8), p.1160-1169 |
| issn | 0941-1291 1436-2813 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2618914322 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Medicine Medicine & Public Health Original Article Surgery Surgical Oncology |
| title | The preoperative pan-immune-inflammation value is a novel prognostic predictor for with stage I–III colorectal cancer patients undergoing surgery |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T04%3A13%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20preoperative%20pan-immune-inflammation%20value%20is%20a%20novel%20prognostic%20predictor%20for%20with%20stage%20I%E2%80%93III%20colorectal%20cancer%20patients%20undergoing%20surgery&rft.jtitle=Surgery%20today%20(Tokyo,%20Japan)&rft.au=Sato,%20Shun&rft.date=2022-08-01&rft.volume=52&rft.issue=8&rft.spage=1160&rft.epage=1169&rft.pages=1160-1169&rft.issn=0941-1291&rft.eissn=1436-2813&rft_id=info:doi/10.1007/s00595-021-02448-6&rft_dat=%3Cproquest_cross%3E2618914322%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2618914322&rft_id=info:pmid/35015151&rfr_iscdi=true |